{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:17Z","timestamp":1793766437563,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102638","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:19:42Z","timestamp":1785424782000},"page":"102638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":false,"given":"Chiara","family":"Mercinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-7821","authenticated-orcid":false,"given":"Giuseppe","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni L.","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7109-2429","authenticated-orcid":false,"given":"Antonio","family":"Cigliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida A.","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-2338","authenticated-orcid":false,"given":"Valentina","family":"Tateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0760-0326","authenticated-orcid":false,"given":"Debora","family":"Serafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6550-4684","authenticated-orcid":false,"given":"Gualtiero","family":"Guandalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lacava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7884-9150","authenticated-orcid":false,"given":"Gaia","family":"Latini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-2596","authenticated-orcid":false,"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clgc.2026.102638_bib0001","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.3390\/cancers17244017","article-title":"The management of muscle invasive bladder cancer: state of the art and future perspectives","volume":"17","author":"Cigliola","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102638_bib0002","unstructured":"Van der Heijden, et al. Muscle-Invasive and Metastatic Bladder Cancer. EAU Guidelines. Edn. presented at the EAU Annual Congress London 2026. ISBN 978-94-92671-32-5."},{"issue":"19","key":"10.1016\/j.clgc.2026.102638_bib0003","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"7_Suppl","key":"10.1016\/j.clgc.2026.102638_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: randomized, open-label phase 3 KEYNOTE-B15 study. In: ASCO GU","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102638_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(26)00050-1","article-title":"Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study","author":"Necchi","year":"2026","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2026.102638_bib0006","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102638_bib0007","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MOU.0000000000001295","article-title":"Immunotherapy toxicities in genito-urinary cancers: insights and challenges for clinicians","volume":"35","author":"Mercinelli","year":"2025","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102638_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2020.01.003","article-title":"Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102638_bib0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102638_bib0010","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2026.102638_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2026.01.015","article-title":"Updated 5-year survival results from PURE-01, a phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer","author":"Tateo","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102638_bib0012","article-title":"First results of NURE-combo: a phase II study of neoadjuvant nivolumab and nab-paclitaxel, followed by postsurgical adjuvant nivolumab, for muscle-invasive bladder cancer","author":"Mercinelli","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102638_bib0013","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.233020","article-title":"Neoadjuvant chemotherapy VI-RADS scores for assessing muscle-invasive bladder cancer response to neoadjuvant immunotherapy with multiparametric MRI","volume":"313","author":"Brembilla","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.clgc.2026.102638_bib0014","article-title":"Vesical imaging-reporting and data system use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer","author":"Necchi","year":"2023","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.clgc.2026.102638_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.clgc.2026.102638_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104420","article-title":"The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies","volume":"200","author":"Daher","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102638_bib0017","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102638_bib0018","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/fon-2022-0868","article-title":"IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery","volume":"19","author":"Jackson-Spence","year":"2023","journal-title":"Future Oncol"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2026.102638_bib0019","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"Ghatalia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102638_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102638_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.clgc.2026.102638_bib0022","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jnci\/djaa076","article-title":"Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"113","author":"Bandini","year":"2021","journal-title":"JNCI"},{"issue":"6","key":"10.1016\/j.clgc.2026.102638_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102214","article-title":"Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study","volume":"22","author":"Reike","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102638_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00289","article-title":"Comprehensive comparison of somatic, germline, and immune cell profiles in upper tract and bladder urothelial carcinoma","author":"Yuen","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102638_bib0025","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3390\/curroncol29030117","article-title":"Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies","volume":"29","author":"Voutsadakis","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clgc.2026.102638_bib0026","article-title":"Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: primary results of the SURE-01 trial","author":"Necchi","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:15:15Z","timestamp":1793765715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001382"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102638","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102638"}}